BioMedical Enterprises

BioMedical Enterprises Inc. (BME) is a biotechnology startup established in 1998 with the aim of researching, developing, and bringing innovative medical products to market. The company's flagship offering, the BME needle, targets the reduction of patient complications associated with hemodialysis, ultimately increasing revenue for dialysis clinics and decreasing costs for medical insurers. This advanced dialysis needle addresses the prevalent issue of clotting and occlusion of vascular access, a major concern for dialysis clinics, patients, and insurers. Furthermore, the BME needle potentially mitigates inflammation and oxidative stress, further minimizing medical complications.

BME is actively seeking investment to commercialize the needle and is currently in the process of securing government approval. As part of its funding efforts, the company has received approximately $1.0 million in grants from the U.S. National Institute of Health for research and development. Additionally, the latest recorded investment in the company was a $862.87K Venture Round investment on 08 June 2009, with the details of the investors undisclosed.

Based in the United States, BioMedical Enterprises is poised to make a significant impact in the biotechnology industry with its innovative medical products, particularly the BME needle that aims to revolutionize the dialysis sector. The company's potential to address critical issues in the healthcare sector and its progress in securing government approvals make it an attractive prospect for investors looking to contribute to groundbreaking advancements in medical technology.